Role of Regulatory Immune Cells in Tumour Microenvironment (TME) DOI
Mohammad Umer Sharif Shohan, Dipankor Chatterjee,

Tasmiha Amin Oishy

et al.

Interdisciplinary cancer research, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy DOI
Suling Xu,

Qing-Qing Wang,

Wenxue Ma

et al.

Cytokine & Growth Factor Reviews, Journal Year: 2024, Volume and Issue: 76, P. 12 - 21

Published: Feb. 28, 2024

Language: Английский

Citations

12
The next frontier in immunotherapy: potential and challenges of CAR-macrophages DOI Creative Commons
Jing Li,

Ping Chen,

Wenxue Ma

et al.

Experimental Hematology and Oncology, Journal Year: 2024, Volume and Issue: 13(1)

Published: Aug. 5, 2024

Abstract Chimeric antigen receptor macrophage (CAR-MΦ) represents a significant advancement in immunotherapy, especially for treating solid tumors where traditional CAR-T therapies face limitations. CAR-MΦ offers promising approach to target and eradicate tumor cells by utilizing macrophages’ phagocytic antigen-presenting abilities. However, challenges such as the complex microenvironment (TME), variability expression, immune suppression limit their efficacy. This review addresses these issues, exploring mechanisms of action, optimal construct designs, interactions within TME. It also delves into ex vivo manufacturing CAR-MΦ, discussing autologous allogeneic sources importance stringent quality control. The potential synergies integrating with existing cancer like checkpoint inhibitors conventional chemotherapeutics are examined highlight possible enhanced treatment outcomes. Furthermore, regulatory pathways scrutinized alongside established protocols cells, identifying unique considerations essential clinical trials market approval. Proposed safety monitoring frameworks aim manage adverse events, cytokine release syndrome, crucial patient safety. Consolidating current research insights, this seeks refine therapeutic applications, overcome barriers, suggest future directions transition from experimental platforms standard care options.

Language: Английский

Citations

12
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions. DOI Creative Commons

Varsha Godakhindi,

Mubin Tarannum,

Sudip Kumar Dam

et al.

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(20)

Published: April 23, 2024

Abstract Cancer immunotherapy recently transforms the traditional approaches against various cancer malignancies. Immunotherapy includes systemic and local treatments to enhance immune responses involves strategies such as checkpoints, vaccines, modulatory agents, mimetic antigen‐presenting cells, adoptive cell therapy. Despite promising results, these still suffer from several limitations including lack of precise delivery immune‐modulatory agents target cells off‐target toxicity, among others, that can be overcome using nanotechnology. Mesoporous silica nanoparticles (MSNs) are investigated improve aspects attributed advantageous structural features this nanomaterial. MSNs engineered alter their properties size, shape, porosity, surface functionality, adjuvanticity. This review explores immunological use vehicles for immune‐adjuvants, (APCs). The also details current remodel tumor microenvironment positively reciprocate toward anti‐tumor in combination with other therapies photodynamic/thermal therapeutic effect cancer. Last, present demands future scenarios discussed.

Language: Английский

Citations

9
Design, synthesis, characterization and biological screening of novel thiosemicarbazones and their derivatives with potent antibacterial and antidiabetic activities DOI

Waseem Shoukat,

Mazhar Hussain,

Awais Ali

et al.

Journal of Molecular Structure, Journal Year: 2024, Volume and Issue: 1320, P. 139614 - 139614

Published: Aug. 18, 2024

Language: Английский

Citations

9
mRNA vaccines: a new era in vaccine development DOI

Shubhra Chandra,

Jennifer C Wilson,

David M. Good

et al.

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Journal Year: 2024, Volume and Issue: 32(10), P. 1543 - 1564

Published: Jan. 1, 2024

The advent of RNA therapy, particularly through the development mRNA cancer vaccines, has ushered in a new era field oncology. This article provides concise overview key principles, recent advancements, and potential implications vaccines as groundbreaking modality treatment. represent revolutionary approach to combatting by leveraging body's innate immune system. These are designed deliver specific sequences encoding cancer-associated antigens, prompting system recognize mount targeted response against malignant cells. personalized adaptive nature holds immense for addressing heterogeneity tailoring treatments individual patients. Recent breakthroughs exemplified success COVID-19 have accelerated their application platform's versatility allows rapid adaptation vaccine candidates various types, presenting an agile promising avenue therapeutic intervention. Clinical trials demonstrated encouraging results terms safety, immunogenicity, efficacy. Pioneering candidates, such BioNTech's BNT111 Moderna's mRNA-4157, exhibited outcomes targeting melanoma solid tumors, respectively. successes underscore elicit robust durable anti-cancer responses. While great promise, challenges manufacturing complexities cost considerations need be addressed widespread adoption. scalable cost-effective processes, along with ongoing clinical research, will pivotal realizing full vaccines. Overall, cutting-edge that promise transforming As research progresses, refining processes crucial advancing these from mainstream oncology practice, offering hope patients fight cancer.

Language: Английский

Citations

8
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy DOI Creative Commons

Baofa Yu,

Shengwen Shao, Wenxue Ma

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: unknown, P. 217350 - 217350

Published: Nov. 1, 2024

Pancreatic cancer remains one of the most challenging malignancies to treat due its late-stage diagnosis, aggressive progression, and high resistance existing therapies. This review examines latest advancements in early detection, therapeutic strategies, with a focus on emerging biomarkers, tumor microenvironment (TME) modulation, integration artificial intelligence (AI) data analysis. We highlight promising including microRNAs (miRNAs) circulating DNA (ctDNA), that offer enhanced sensitivity specificity for early-stage diagnosis when combined multi-omics panels. A detailed analysis TME reveals how components such as cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix (ECM) contribute therapy by creating immunosuppressive barriers. also discuss interventions target these components, aiming improve drug delivery overcome evasion. Furthermore, AI-driven analyses are explored their potential interpret complex data, enabling personalized treatment strategies real-time monitoring response. conclude identifying key areas future research, clinical validation regulatory frameworks AI applications, equitable access innovative comprehensive approach underscores need integrated, outcomes pancreatic cancer.

Language: Английский

Citations

6
NK/DC crosstalk-modulating antitumor activity via Sema3E/PlexinD1 axis for enhanced cancer immunotherapy DOI
Awais Ali, Abdulaziz Alamri,

Azraida Hajar

et al.

Immunologic Research, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 5, 2024

Language: Английский

Citations

3
Enhancing Medical Education: Implementing a Cancer Immunotherapy Elective for Medical Students (Preprint) DOI Creative Commons

Mark Raynor,

Rivers A Hock,

Brandon Godinich

et al.

Published: Jan. 22, 2025

UNSTRUCTURED The rapid advancements in cancer immunotherapy have revolutionized the landscape of oncology, offering new hope and treatment paradigms for patients with various cancers. Cancer is a complex evolving field transformative potential, necessitating its inclusion undergraduate medical education. We describe design implementation novel, online elective fourth-year students. was well received by students enhanced their understanding interest field. vital step towards enhancing A blueprint provided aim to bridge gap between cutting-edge research, basic science clinical applications, prepare next generation physicians meet challenges modern oncology.

Language: Английский

Citations

0
Unveiling the key roles in esophageal cancer drug resistance from a genetic perspective: the interplay between cytokines and immune cell phenotypes DOI Creative Commons

Huishen Yan,

Zhiwu Lin, Jieying Zhang

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: April 1, 2025

Language: Английский

Citations

0
An antibody targeting an immune checkpoint molecule BTN2A2 enhances anti-tumor immunity DOI
Xiao Li,

Rong Hu,

Wei Chen

et al.

Neoplasia, Journal Year: 2025, Volume and Issue: 65, P. 101161 - 101161

Published: April 21, 2025

Language: Английский

Citations

0